Merck’s Keytruda(pembrolizumab) Receives 5 Approvals from PMDA, Japan across 3 Indications

 Merck’s Keytruda(pembrolizumab) Receives 5 Approvals from PMDA, Japan across 3 Indications

Merck’s Keytruda(pembrolizumab) Receives 5 Approvals from PMDA, Japan across 3 Indications

Shots:

•      Out of 5 approvals three are for NSCLC patients, one for Melanoma and one for Microsatellite Instability-High (MSI-H) solid tumor patients
•      Keytruda got approved as monotherapy in 1L PD-L1 positive NSCLC patients based on Keynote-042, one in 1L non-squamous patients in combination with pemetrexed and PT-CT based on keynote-189 and another for 1L squamous NSCLC patients in combo with nab/paclitaxel+ carboplatin based on keynote-407 both regardless of PD-L1 expression
•     Approval in melanoma as adjuvant monotherapy based on keynote-054 and approval in MSI-H solid tumor for 2L post companion diagnosis by Falco based on keynote-164, 158
•    Additionally, dosage in adjuvant has been changed from IV 2mg/kg to 200mg fixed dose

Click here to read full press release/ article | Ref: Merck | Image: Boyd Mechanical Corp

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post